• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.

作者信息

Hill Brian T, Roberts Zachary J, Xue Allen, Rossi John M, Smith Mitchell R

机构信息

Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.

Kite, A Gilead Company, Santa Monica, CA, USA.

出版信息

Bone Marrow Transplant. 2020 Jun;55(6):1184-1187. doi: 10.1038/s41409-019-0657-3. Epub 2019 Aug 30.

DOI:10.1038/s41409-019-0657-3
PMID:31471571
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7269903/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c47/7269903/0a67e1829732/41409_2019_657_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c47/7269903/0a67e1829732/41409_2019_657_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2c47/7269903/0a67e1829732/41409_2019_657_Fig1_HTML.jpg

相似文献

1
Rapid tumor regression from PD-1 inhibition after anti-CD19 chimeric antigen receptor T-cell therapy in refractory diffuse large B-cell lymphoma.在难治性弥漫性大B细胞淋巴瘤中，抗CD19嵌合抗原受体T细胞疗法后，PD-1抑制导致肿瘤快速消退。
Bone Marrow Transplant. 2020 Jun;55(6):1184-1187. doi: 10.1038/s41409-019-0657-3. Epub 2019 Aug 30.
2
Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma.嵌合抗原受体T细胞疗法对复发/难治性大B细胞淋巴瘤老年脆弱患者的疗效与安全性
Haematologica. 2021 Jan 1;106(1):255-258. doi: 10.3324/haematol.2019.243246.
3
Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.嵌合抗原受体T细胞疗法治疗HIV相关弥漫性大B细胞淋巴瘤：病例报告及管理建议
Bone Marrow Transplant. 2021 Mar;56(3):679-682. doi: 10.1038/s41409-020-01018-7. Epub 2020 Aug 6.
4
Prognostic value of early positron emission tomography in patients with large B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy.早期正电子发射断层扫描在接受抗CD19嵌合抗原受体T细胞疗法治疗的大B细胞淋巴瘤患者中的预后价值
Haematologica. 2023 Dec 1;108(12):3433-3437. doi: 10.3324/haematol.2022.282345.
5
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.将抗 CD19 CAR T 细胞疗法转化为复发/难治性弥漫性大 B 细胞淋巴瘤的临床实践。
Blood. 2018 Aug 23;132(8):777-781. doi: 10.1182/blood-2018-04-839217. Epub 2018 Jun 18.
6
CAR-T cell therapy is superior to standard of care as second-line therapy for large B-cell lymphoma: A systematic review and meta-analysis.嵌合抗原受体T细胞（CAR-T）疗法作为大B细胞淋巴瘤二线治疗优于标准治疗：一项系统评价和荟萃分析。
Br J Haematol. 2023 Jan;200(1):e4-e5. doi: 10.1111/bjh.18506. Epub 2022 Oct 25.
7
[Relapse mechanism and coping strategies of CD19 chimeric antigen receptor T cells in the treatment of diffuse large B-cell lymphoma].[CD19嵌合抗原受体T细胞治疗弥漫性大B细胞淋巴瘤的复发机制及应对策略]
Zhonghua Xue Ye Xue Za Zhi. 2022 Sep 14;43(9):788-792. doi: 10.3760/cma.j.issn.0253-2727.2022.09.014.
8
Primary resistance to CD19-directed chimeric antigen receptor T-cell therapy in T-cell/histiocyte-rich large B-cell lymphoma.T细胞/组织细胞丰富的大B细胞淋巴瘤对CD19导向的嵌合抗原受体T细胞疗法的原发性耐药
Blood. 2021 Jun 17;137(24):3454-3459. doi: 10.1182/blood.2020009148.
9
Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience.接受抗CD-19嵌合抗原受体T细胞疗法治疗大B细胞淋巴瘤患者中细胞因子释放综合征和神经毒性与疗效的真实世界关联：梅奥诊所的经验
Leuk Lymphoma. 2024 Mar;65(3):389-393. doi: 10.1080/10428194.2023.2285236. Epub 2023 Nov 30.
10
Phase II trial of co-administration of CD19- and CD20-targeted chimeric antigen receptor T cells for relapsed and refractory diffuse large B cell lymphoma.CD19 和 CD20 靶向嵌合抗原受体 T 细胞联合给药治疗复发/难治性弥漫性大 B 细胞淋巴瘤的 II 期临床试验。
Cancer Med. 2020 Aug;9(16):5827-5838. doi: 10.1002/cam4.3259. Epub 2020 Jul 1.

引用本文的文献

1
Current Issues and Future Perspectives of Targeted Therapies in Primary Mediastinal Large B-Cell Lymphoma.原发性纵隔大B细胞淋巴瘤靶向治疗的当前问题与未来展望
J Clin Med. 2025 Feb 11;14(4):1191. doi: 10.3390/jcm14041191.
2
Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review.癌症免疫反应性的理解与治疗性调控进展：癌症免疫治疗学会（SITC）综述
J Immunother Cancer. 2025 Jan 16;13(1):e008876. doi: 10.1136/jitc-2024-008876.
3
Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
严重毒性，但在大B细胞淋巴瘤中免疫检查点抑制剂治疗后CAR T细胞长期持续存在。
Leuk Lymphoma. 2025 Mar;66(3):535-540. doi: 10.1080/10428194.2024.2430703. Epub 2024 Nov 20.
4
PD-1 downregulation enhances CAR-T cell antitumor efficiency by preserving a cell memory phenotype and reducing exhaustion.PD-1 下调通过维持细胞记忆表型和减少衰竭来增强 CAR-T 细胞的抗肿瘤效率。
J Immunother Cancer. 2024 Apr 8;12(4):e008429. doi: 10.1136/jitc-2023-008429.
5
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma.抗 PD-L1 抗体起始时机影响 CD19 CAR T 细胞治疗大 B 细胞淋巴瘤的疗效/毒性。
Blood Adv. 2024 Jan 23;8(2):453-467. doi: 10.1182/bloodadvances.2023011287.
6
Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review.免疫检查点抑制剂联合或序贯治疗与嵌合抗原受体 T 细胞疗法治疗血液系统恶性肿瘤的系统评价。
Int J Mol Sci. 2023 Sep 30;24(19):14780. doi: 10.3390/ijms241914780.
7
Learning from the microbes: exploiting the microbiome to enforce T cell immunotherapy.从微生物中学习：利用微生物组增强 T 细胞免疫疗法。
Front Immunol. 2023 Sep 18;14:1269015. doi: 10.3389/fimmu.2023.1269015. eCollection 2023.
8
PD-1 CAR-T cells provide superior protection against solid tumors.PD-1 CAR-T 细胞为实体肿瘤提供了更好的保护。
Front Immunol. 2023 Jun 14;14:1187850. doi: 10.3389/fimmu.2023.1187850. eCollection 2023.
9
Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphoma.来那度胺克服了弥漫性大 B 细胞淋巴瘤临床前模型中对第三代 CD19-CAR-T 细胞治疗的耐药性。
Cell Oncol (Dordr). 2023 Aug;46(4):1143-1157. doi: 10.1007/s13402-023-00833-6. Epub 2023 May 23.
10
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions.CAR-T 治疗失败后接受检查点抑制治疗侵袭性 B 细胞淋巴瘤的疗效：来自 15 家美国机构的结果。
Blood Adv. 2023 Aug 22;7(16):4528-4538. doi: 10.1182/bloodadvances.2023010016.